Martindale September 2023 Update

This update contains 22 new monographs, 1 existing monograph update, and 2 existing treatment reviews updates. Preparations have been updated for 4 countries.

New Monographs

• Atoltivimab, maftivimab, and odesivimab are Zaire ebolavirus glycoprotein-directed human monoclonal antibodies used together for the treatment of Zaire ebolavirus infection.
• Belantamab mafodotin is an antibody-drug conjugate consisting of a B-cell maturation antigen (BCMA) directed monoclonal antibody conjugated to a microtubule inhibitor; it is used for the treatment of relapsed or refractory multiple myeloma.
• Berotralstat is a plasma kallikrein inhibitor used for prophylaxis of acute attacks of hereditary angioedema.
• Bulevirtide is a sodium-bile acid co-transporter inhibitor used for the treatment of chronic hepatitis D in compensated liver disease.
• Cabotegravir is an HIV-integrase inhibitor used with rilpivirine for the treatment of HIV infection, and as monotherapy for pre-exposure prophylaxis.
• Casimersen, an antisense oligonucleotide, is given for the treatment of Duchenne muscular dystrophy caused by mutations in the dystrophin gene that are amenable to treatment with exon 45 skipping.
• Deucravacitinib is an inhibitor of tyrosine kinase 2, which is a member of the Janus kinase (JAK) family. It is used for the treatment of moderate to severe plaque psoriasis.
• Futibatinib is a tyrosine kinase inhibitor used in the treatment of locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene alterations.
• Golodirsen, an antisense oligonucleotide, is given for the treatment of Duchenne muscular dystrophy caused by mutations in the dystrophin gene that are amenable to treatment with exon 53 skipping.
• Lumasiran is a small interfering ribonucleic acid (siRNA) used in the treatment of primary hyperoxaluria type 1.
• Mirvetuximab soravtansine is an antibody-drug conjugate consisting of a folate receptor alpha-directed monoclonal antibody conjugated to DM4, a microtubule inhibitor. It is used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Omidenepag is a prostaglandin E2 receptor agonist. It is used as the isopropyl ester to reduce elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.
• Pacritinib is an inhibitor of the Janus kinase JAK2 and FMS-like tyrosine kinase 3 (FLT3) used in the treatment of myelofibrosis.
• Pegcetacoplan is a synthetic pegylated cyclic peptide that acts as a complement blocker by inhibiting complement activation at the C3 protein. It is used to reduce haemolysis in patients with paroxysmal nocturnal haemoglobinuria. It is also used for the treatment of geographic atrophy caused by non-neovascular (dry) age-related macular degeneration.
• Pexidartinib is a tyrosine kinase inhibitor used in the treatment of tenosynovial giant cell tumour.
• Relatlimab is a human immunoglobulin G4 monoclonal antibody that is used for the treatment of unresectable or metastatic melanoma.
• Spesolimab is a humanised monoclonal antibody that binds to and blocks the interleukin-36 receptor. It is used for the treatment of generalised pustular psoriasis flares.
• Tirzepatide is a long-acting dual glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It is used in the treatment of type 2 diabetes mellitus.
• Trilaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 used in the prevention of chemotherapy-induced myelosuppression.
• Viltolarsen, an antisense oligonucleotide, is given for the treatment of Duchenne muscular dystrophy caused by mutations in the dystrophin gene that are amenable to treatment with exon 53 skipping.

Selective Updates – some new, re-validated or changed information

Monographs

• Mepolizumab

Treatment reviews

• COVID-19
• Primary hyperoxaluria

Proprietary Preparations and Manufacturers updated for the following countries and regions:

• Greece
• India
• UK†
• USA†

† Countries updated on an ongoing basis